Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional changes in the breast cancer cell line MCF7 rendered resistant to the cationic drug siramesine

ABSTRACT: Transcriptional changes in the breast cancer cell line MCF7 rendered resistant to the cationic drug siramesine

PROVIDER: PRJNA539897 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8962155.fastq.gz	Fastqsanger.gz
	SRR8962156_1.fastq.gz	Fastqsanger.gz
	SRR8962156_2.fastq.gz	Fastqsanger.gz
	SRR8962157.fastq.gz	Fastqsanger.gz
	SRR8962158_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Transcriptional changes in the breast cancer cell line MCF7 rendered resistant to the cationic drug siramesine

Project description:Repurpusing cationic amphiphilic drugs (CADs) may be enhance the effect of chemotherapy in cancer treatment. In order to understand the molecular mechanism, we created cell lines resistant to the CAD siramesine by growing them for 6 months in increasing concentrations of siramesine. Parental and resistant cell lines were subjected to RNAseq and revealed diffentially expressed genes in ca+ and cAMP signalling pathways.

2019-04-27 | GSE130363 | GEO

Genetic and transcriptional variation alters cancer cell line drug response [MCF7]

Project description:Genetic and transcriptional variation alters cancer cell line drug response [MCF7]

| PRJNA471584 | ENA

Genetic and transcriptional variation alters cancer cell line drug response [MCF7]

Project description:10X Genomics single cell RNAseq of MCF7 cells Human cancer cell lines are the workhorse of cancer research. While cell lines are known to evolve in culture, the extent of the resultant genetic and transcriptional heterogeneity and its functional consequences remain understudied. Here, genomic analyses of 106 cell lines grown in two laboratories revealed extensive clonal diversity. Follow-up comprehensive genomic characterization of 27 strains of the common breast cancer cell line MCF7 uncovered rapid genetic diversification. Similar results were obtained with multiple strains of 13 additional cell lines. Importantly, genetic changes were associated with differential activation of gene expression programs and marked differences in cell morphology and proliferation. Barcoding experiments showed that cell line evolution occurs as a result of positive clonal selection that is highly sensitive to culture conditions. Analyses of single cell-derived clones showed that ongoing instability quickly translates into cell line heterogeneity. Testing of the 27 MCF7 strains against 321 anti-cancer compounds uncovered strikingly disparate drug response: at least 75% of compounds that strongly inhibited some strains were completely inactive in others. This study documents the extent, origin and consequence of genetic variation within cell lines, and provides a framework for researchers to measure such variation in efforts to support maximally reproducible cancer research.

2018-08-01 | GSE114459 | GEO

Identification of ZNF217 interactors in MCF7 breast cancer cell line

Project description:Identification of TRPS1 interactors in MCF7 breast cancer cell line.

2018-07-17 | PXD010312 | Pride

HAX1-interactome in breast cancer cell line (MCF7)

Project description:The MCF7 cell line represents a typical epithelial cell line and corresponds to luminal A breast cancer (estrogen-responsive). Overexpression of HAX1 was demonstrated in MCF7 cell line as well as in breast cancer samples, suggesting a role of HAX1 in breast cancer progression. HAX1 is a 32-kDa protein of unknown structure, involved in the regulation of apoptosis, cell migration and calcium homeostasis. It was also shown to bind mRNA. Scarcity of structural elements and the presence of a disordered region, inferred from HAX1 sequence, suggests that HAX1 is intrinsically disordered, and may have many protein-protein interactions. So far about 40 different proteins were characterized as HAX1 protein partners. In the present work, applying immunoaffinity chromatography coupled with mass spectrometry, we identified new candidates for HAX1 binding partners in breast cancer cells. Newly identified proteins may be divided into three, partially overlapping groups: cytoskeleton-associated proteins, GTP-ase associated proteins and RNA-binding proteins. These results imply that HAX1 has more protein partners than hitherto described. Subsequent analysis of these interactions may shed some light into molecular mechanisms of HAX1 functions.

2019-11-14 | PXD007888 | Pride

Genetic and transcriptional variation alters cancer cell line drug response [MCF7 strain AA]

Project description:10X Genomics single cell RNAseq of MCF7 cells treated with bortezomib. Human cancer cell lines are the workhorse of cancer research. While cell lines are known to evolve in culture, the extent of the resultant genetic and transcriptional heterogeneity and its functional consequences remain understudied. Here, genomic analyses of 106 cell lines grown in two laboratories revealed extensive clonal diversity. Follow-up comprehensive genomic characterization of 27 strains of the common breast cancer cell line MCF7 uncovered rapid genetic diversification. Similar results were obtained with multiple strains of 13 additional cell lines. Importantly, genetic changes were associated with differential activation of gene expression programs and marked differences in cell morphology and proliferation. Barcoding experiments showed that cell line evolution occurs as a result of positive clonal selection that is highly sensitive to culture conditions. Analyses of single cell-derived clones showed that ongoing instability quickly translates into cell line heterogeneity. Testing of the 27 MCF7 strains against 321 anti-cancer compounds uncovered strikingly disparate drug response: at least 75% of compounds that strongly inhibited some strains were completely inactive in others. This study documents the extent, origin and consequence of genetic variation within cell lines, and provides a framework for researchers to measure such variation in efforts to support maximally reproducible cancer research.

2018-08-01 | GSE114461 | GEO

Genetic and transcriptional variation alters cancer cell line drug response [MCF7 strain L]

2018-08-01 | GSE114460 | GEO

FOXK2 geneknockown induces transcriptomic changes in breast cancer cell line MCF7

Project description:FOXK2 geneknockown induces transcriptomic changes in breast cancer cell line MCF7

| PRJNA962014 | ENA

Genetic and transcriptional variation alters cancer cell line drug response [MCF7 strain L]

Project description:Genetic and transcriptional variation alters cancer cell line drug response [MCF7 strain L]

| PRJNA471583 | ENA

Genetic and transcriptional variation alters cancer cell line drug response [MCF7 strain AA]

Project description:Genetic and transcriptional variation alters cancer cell line drug response [MCF7 strain AA]

| PRJNA471582 | ENA